^
Association details:
Biomarker:NRAS G13N
Cancer:Multiple Myeloma
Drug:PD173074 (Tyrosine kinase inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

Excerpt:
In all assays, sensitivity to PD173074, AZ8010 or AZD4547 was confined to those cells...the absence of deregulated FGFR (MM.1S) or the presence of NRASG13N (H929) was associated with resistance to FGFRi.
DOI:
10.1038/onc.2012.319